Akcea Therapeutics (AKCA) Misses Q1 EPS, Revs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Akcea Reports Financial Results and Highlights for First Quarter 2019
May 8, 2019 4:05 PM EDTAchieved First Quarter 2019 TEGSEDI® (inotersen) Global Net Product Revenues of $7 Million
 Novartis exercised its option to license AKCEA-APO(a)-LRx
Received marketing authorization for WAYLIVRA® (volanesorsen) in E.U.
Conference Call Webcast Wednesday, May 8, 4:30 p.m. ET... More
